Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

被引:679
|
作者
Stringhini, Silvia [1 ,11 ,18 ]
Wisniak, Ania [15 ]
Piumatti, Giovanni [1 ,19 ]
Azman, Andrew S. [15 ,20 ]
Lauer, Stephen A. [20 ]
Baysson, Helene [11 ]
De Ridder, David [11 ]
Petrovic, Dusan [1 ,18 ]
Schrempft, Stephanie [1 ]
Marcus, Kailing [1 ]
Yerly, Sabine [2 ,3 ,4 ]
Vernez, Isabelle Arm [3 ,4 ]
Keiser, Olivia [15 ]
Hurst, Samia [16 ]
Posfay-Barbe, Klara M. [5 ]
Trono, Didier [21 ]
Pittet, Didier [6 ,7 ]
Getaz, Laurent [8 ,11 ]
Chappuis, Francois [9 ,11 ]
Eckerle, Isabella [3 ,4 ,12 ]
Vuilleumier, Nicolas [2 ,14 ]
Meyer, Benjamin [13 ,17 ]
Flahault, Antoine [9 ,11 ,15 ]
Kaiser, Laurent [3 ,4 ,10 ,14 ]
Guessous, Idris [1 ,11 ]
机构
[1] Geneva Univ Hosp, Div Primary Care, CH-1205 Geneva, Switzerland
[2] Geneva Univ Hosp, Div Lab Med, Geneva, Switzerland
[3] Geneva Univ Hosp, Geneva Ctr Emerging Viral Dis, Geneva, Switzerland
[4] Geneva Univ Hosp, Lab Virol, Geneva, Switzerland
[5] Geneva Univ Hosp, Div Gen Pediat, Geneva, Switzerland
[6] Geneva Univ Hosp, Infect Prevent & Control Program, Geneva, Switzerland
[7] Geneva Univ Hosp, World Hlth Org Collaborating Ctr Patient Safety, Geneva, Switzerland
[8] Geneva Univ Hosp, Div Penitentiary Med, Geneva, Switzerland
[9] Geneva Univ Hosp, Div Trop & Humanitarian Med, Geneva, Switzerland
[10] Geneva Univ Hosp, Div Infect Dis, Geneva, Switzerland
[11] Univ Geneva, Dept Hlth & Community Med, Fac Med, Geneva, Switzerland
[12] Univ Geneva, Fac Med, Dept Microbiol & Mol Med, Geneva, Switzerland
[13] Univ Geneva, Dept Pathol & Immunol, Fac Med, Ctr Vaccinol, Geneva, Switzerland
[14] Univ Geneva, Dept Med, Fac Med, Geneva, Switzerland
[15] Univ Geneva, Fac Med, Inst Global Hlth, Geneva, Switzerland
[16] Univ Geneva, Inst Eth, Hist, Humanites, Geneva, Switzerland
[17] Univ Geneva, Ctr Vaccinol, Dept Pathol & Immunol, Geneva, Switzerland
[18] Univ Lausanne, Univ Ctr Gen Med & Publ Hlth, Lausanne, Switzerland
[19] Univ Svizzera Italiana, Fac BioMed, Lugano, Switzerland
[20] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[21] Ecole Polytech Fed Lausanne, Sch Life Sci, Lausanne, Switzerland
来源
LANCET | 2020年 / 396卷 / 10247期
关键词
D O I
10.1016/S0140-6736(20)31304-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Assessing the burden of COVID-19 on the basis of medically attended case numbers is suboptimal given its reliance on testing strategy, changing case definitions, and disease presentation. Population-based serosurveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies provide one method for estimating infection rates and monitoring the progression of the epidemic. Here, we estimate weekly seroprevalence of anti-SARS-CoV-2 antibodies in the population of Geneva, Switzerland, during the epidemic. Methods The SEROCoV-POP study is a population-based study of former participants of the Bus Sante study and their household members. We planned a series of 12 consecutive weekly serosurveys among randomly selected participants from a previous population-representative survey, and their household members aged 5 years and older. We tested each participant for anti-SARS-CoV-2-IgG antibodies using a commercially available ELISA. We estimated seroprevalence using a Bayesian logistic regression model taking into account test performance and adjusting for the age and sex of Geneva's population. Here we present results from the first 5 weeks of the study. Findings Between April 6 and May 9, 2020, we enrolled 2766 participants from 1339 households, with a demographic distribution similar to that of the canton of Geneva. In the first week, we estimated a seroprevalence of 4 center dot 8% (95% CI 2 center dot 4-8 center dot 0, n=341). The estimate increased to 8 center dot 5% (5 center dot 9-11 center dot 4, n=469) in the second week, to 10 center dot 9% (7 center dot 9-14 center dot 4, n=577) in the third week, 6 center dot 6% (4 center dot 3-9 center dot 4, n=604) in the fourth week, and 10 center dot 8% (8 center dot 2-13 center dot 9, n=775) in the fifth week. Individuals aged 5-9 years (relative risk [RR] 0 center dot 32 [95% CI 0 center dot 11-0 center dot 63]) and those older than 65 years (RR 0 center dot 50 [0 center dot 28-0 center dot 78]) had a significantly lower risk of being seropositive than those aged 20-49 years. After accounting for the time to seroconversion, we estimated that for every reported confirmed case, there were 11 center dot 6 infections in the community. Interpretation These results suggest that most of the population of Geneva remained uninfected during this wave of the pandemic, despite the high prevalence of COVID-19 in the region (5000 reported clinical cases over <2 center dot 5 months in the population of half a million people). Assuming that the presence of IgG antibodies is associated with immunity, these results highlight that the epidemic is far from coming to an end by means of fewer susceptible people in the population. Further, a significantly lower seroprevalence was observed for children aged 5-9 years and adults older than 65 years, compared with those aged 10-64 years. These results will inform countries considering the easing of restrictions aimed at curbing transmission. Copyright (c) 2020 Elsevier Ltd. All rights reserved.
引用
收藏
页码:313 / 319
页数:7
相关论文
共 50 条
  • [41] High seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers
    Tesfaye Gelanew
    Berhanu Seyoum
    Andargachew Mulu
    Adane Mihret
    Markos Abebe
    Liya Wassie
    Baye Gelaw
    Abebe Sorsa
    Yared Merid
    Yilkal Muchie
    Zelalem Teklemariam
    Bezalem Tesfaye
    Mahlet Osman
    Gutema Jebessa
    Abay Atinafu
    Tsegaye Hailu
    Antenehe Habte
    Dagaga Kenea
    Anteneh Gadisa
    Desalegn Admasu
    Emnet Tesfaye
    Timothy A. Bates
    Jote Tafese Bulcha
    Rea Tschopp
    Dareskedar Tsehay
    Kim Mullholand
    Rawleigh Howe
    Abebe Genetu
    Fikadu G. Tafesse
    Alemseged Abdissa
    BMC Infectious Diseases, 22
  • [42] Seroprevalence of Anti-SARS-CoV-2 Antibodies among Municipal Staff in the Municipality of Prishtina
    Gashi, Bujar
    Osmani, Vesa
    Halili, Rrezart
    Hoxha, Teuta
    Kamberi, Agron
    Hoti, Nexhmedin
    Agahi, Riaz
    Basha, Vlora
    Berisha, Visar
    Hoxha, Ilir
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (23)
  • [43] Detection of Anti-SARS-CoV-2 Antibodies
    Jahrsdoerfer, Bernd
    Schrezenmeier, Hubert
    TRANSFUSIONSMEDIZIN, 2021, 11 (03) : 182 - 187
  • [44] Large variation in anti-SARS-CoV-2 antibody prevalence among essential workers in Geneva, Switzerland
    Silvia Stringhini
    María-Eugenia Zaballa
    Nick Pullen
    Carlos de Mestral
    Javier Perez-Saez
    Roxane Dumont
    Attilio Picazio
    Francesco Pennacchio
    Yaron Dibner
    Sabine Yerly
    Helene Baysson
    Nicolas Vuilleumier
    Jean-François Balavoine
    Delphine Bachmann
    Didier Trono
    Didier Pittet
    François Chappuis
    Omar Kherad
    Laurent Kaiser
    Andrew S. Azman
    Idris Guessous
    Nature Communications, 12
  • [45] Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposure to adults with COVID-19: Preliminary findings
    Buonsenso, Danilo
    Valentini, Piero
    De Rose, Cristina
    Pata, Davide
    Sinatti, Dario
    Speziale, Domenico
    Ricci, Rosalba
    Carfi, Angelo
    Landi, Francesco
    Ferrari, Vittoria
    De Maio, Flavio
    Palucci, Ivana
    Sanguinetti, Maurizio
    Sali, Michela
    PEDIATRIC PULMONOLOGY, 2021, 56 (06) : 1374 - 1377
  • [46] Seroprevalence of anti-SARS-CoV-2 IgG antibodies among children attending the pediatric hospital in Bamako, Mali (BamaCoV-Kids Study)
    Maiga, Almoustapha Issiaka
    Kodio, Amadou
    Ouedraogo, Salimata Alou
    Balde, Aliou
    Dembele, Penda
    Traore, Fatoumata Tata
    Dolo, Oumar
    Togo, Josue
    Coulibaly, Yacouba Aba
    Sylla, Mariam
    Murphy, Robert L.
    Marcelin, Anne-Genevieve
    Calvez, Vincent
    Diakite, Abdoul Aziz
    Todesco, Eve
    BMC INFECTIOUS DISEASES, 2025, 25 (01)
  • [47] Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population
    Carlos David Araújo Bichara
    Ednelza da Silva Graça Amoras
    Gergiane Lopes Vaz
    Maria Karoliny da Silva Torres
    Maria Alice Freitas Queiroz
    Isabella Pinheiro Costa do Amaral
    Izaura Maria Vieira Cayres Vallinoto
    Cléa Nazaré Carneiro Bichara
    Antonio Carlos Rosário Vallinoto
    BMC Infectious Diseases, 21
  • [48] Seroprevalence of anti-SARS-CoV-2 IgG antibodies: relationship with COVID-19 diagnosis, symptoms, smoking, and method of transmission
    Buhler, Kora-Mareen
    Echeverry-Alzate, Victor
    Calleja-Conde, Javier
    Duran-Gonzalez, Pedro
    Segovia-Rodriguez, Lucia
    Morales-Garcia, Jose A.
    Perez-Wiesner, Mateo
    Cables-Chozas, David
    de Fonseca, Fernando Rodriguez
    Delgado-Iribarren, Alberto
    Merino-Amador, Paloma
    Gonzalez-Romo, Fernando
    Gine, Elena
    Lopez-Moreno, Jose Antonio
    IJID REGIONS, 2022, 4 : 10 - 16
  • [49] Large variation in anti-SARS-CoV-2 antibody prevalence among essential workers in Geneva, Switzerland
    Stringhini, Silvia
    Zaballa, Maria-Eugenia
    Pullen, Nick
    de Mestral, Carlos
    Perez-Saez, Javier
    Dumont, Roxane
    Picazio, Attilio
    Pennacchio, Francesco
    Dibner, Yaron
    Yerly, Sabine
    Baysson, Helene
    Vuilleumier, Nicolas
    Balavoine, Jean-Francois
    Bachmann, Delphine
    Trono, Didier
    Pittet, Didier
    Chappuis, Francois
    Kherad, Omar
    Kaiser, Laurent
    Azman, Andrew S.
    Guessous, Idris
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [50] Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population
    Araujo Bichara, Carlos David
    Graca Amoras, Ednelza da Silva
    Vaz, Gergiane Lopes
    da Silva Torres, Maria Karoliny
    Freitas Queiroz, Maria Alice
    Costa do Amaral, Isabella Pinheiro
    Vieira Cayres Vallinoto, Izaura Maria
    Carneiro Bichara, Clea Nazare
    Rosario Vallinoto, Antonio Carlos
    BMC INFECTIOUS DISEASES, 2021, 21 (01)